You are viewing: Asia Pacific Nuclear Medicine Market analysis
Part of: Nuclear Medicine Market (Global)

The Asia Pacific Nuclear Medicine Market was valued at $1361.1 Million in 2025 and projected to reach to $2850 Million by 2030, representing a compound annual growth rate of 15.9%. The Asia Pacific nuclear medicine market is positioned for exceptional growth through 2030, driven by substantial healthcare infrastructure investments and rising chronic disease prevalence across the region.

Asia Pacific Nuclear Medicine Market Trends and Insights

  • Asia Pacific's growth trajectory reflects increasing healthcare infrastructure investment, rising prevalence of chronic diseases, and expanding access to diagnostic imaging technologies across the region.
  • The market's 15.9% compound annual growth rate significantly outpaces global trends, driven by aging populations and enhanced government healthcare spending in key Asia Pacific economies. Asia Pacific's nuclear medicine sector benefits from technological advancement and growing clinical adoption of positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging.
  • Between 2025 and 2030, Asia Pacific is expected to capture substantial market share as emerging economies modernize their healthcare systems and increase radiopharmaceutical production capacity.
  • Regulatory improvements and rising awareness of early disease detection are accelerating nuclear medicine utilization across Asia Pacific's diverse healthcare markets..

Key Market Statistics

  • CAGR (2025-2030) 15.9% CAGR
  • Market Size, 2025 ~USD 1361.1 Million
  • Forecast, 2030 ~USD 2850 Million
  • Geography Asia Pacific

Asia Pacific Nuclear Medicine Market Overview

Rapid Market Expansion :

Asia Pacific nuclear medicine market is projected to grow from USD 1,361.1 million in 2025 to USD 2,850.0 million by 2030, representing a robust 15.9% CAGR, outpacing the global growth rate of 15.1%.

Healthcare Infrastructure Investment :

Significant capital allocation toward modernizing diagnostic imaging facilities across Asia Pacific nations is driving adoption of nuclear medicine technologies and expanding clinical applications in oncology and cardiology.

Rising Chronic Disease Burden :

Increasing prevalence of cancer, cardiovascular diseases, and neurological disorders across Asia Pacific populations is escalating demand for advanced diagnostic imaging and therapeutic nuclear medicine procedures.

Expanding Regional Access :

Growing availability of radiopharmaceuticals, cyclotrons, and PET/SPECT imaging equipment in emerging Asia Pacific markets is democratizing access to nuclear medicine diagnostics beyond major metropolitan centers.

Asia Pacific Nuclear Medicine Market Dynamics

  • Countries including Japan, China, and India are establishing advanced diagnostic imaging centers and expanding radiopharmaceutical production capabilities, creating a competitive landscape that benefits healthcare providers and patients alike. Regulatory harmonization efforts and increased government funding for cancer screening programs are accelerating market penetration in emerging economies.
  • The region's young, growing population combined with improving healthcare accessibility creates sustained demand for nuclear medicine diagnostics.
  • Strategic partnerships between international medical device manufacturers and regional healthcare systems are expected to further accelerate technology adoption and market expansion through 2030..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • Asia Pacific nuclear medicine market grows from $1,361.1M (2025) to $2,850M (2030) at 15.9% CAGR
    • Asia Pacific's growth rate outpaces global average, driven by aging demographics and healthcare modernization
    • Asia Pacific emerging economies are expanding radiopharmaceutical production and imaging infrastructure
    • Asia Pacific regulatory improvements and disease awareness are accelerating clinical adoption of nuclear medicine

    Nuclear Medicine Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment THERAPEUTIC NUCLEAR MEDICINE (Type)
    Forecast Period 2025–2039
    Growth Rate CAGR of 15.1% from 2025 to 2039
    Largest Segment DIAGNOSTIC PROCEDURES (Procedure)
    Market Size Base Year (Billions) ~USD 10.4 (2025)
    Revenue Forecast (Billions) ~USD 21.01 (2039)
    Segments Covered Type, Application, Procedure, End User

    Asia Pacific Nuclear Medicine Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Type

    • Alpha Emitters
    • Beta Emitters
    • Bone Metastasis
    • Bone Scans
    • Brachytherapy Isotopes
    • Cardiology
    • Cs-131
    • Diagnostic Nuclear Medicine
    • Endocrine Tumors
    • F-18
    • Ga-67
    • I-123
    • I-125
    • I-131
    • Ir-192
    • Lu-177
    • Lymphoma
    • Neurology
    • Oncology
    • Other Beta Emitters
    • Other Brachytherapy Isotopes
    • Other Pet Applications
    • Other Pet Radiopharmaceuticals
    • Other Spect Applications
    • Other Spect Radiopharmaceuticals
    • Other Therapeutic Applications
    • Pd-103
    • Pet Applications
    • Pet Procedures
    • Pet Radiopharmaceuticals
    • Pulmonary Scans
    • Ra-223
    • Rb-82
    • Sm-153
    • Spect Applications
    • Spect Procedures
    • Spect Radiopharmaceuticals
    • Tc-99M
    • Therapeutic Nuclear Medicine
    • Thyroid
    • Tl-201
    • Y-90

    By Application

    • Diagnostic Applications
    • Therapeutic Applications

    By Procedure

    • Diagnostic Procedures
    • Therapeutic Procedures

    By End User

    • Academic & Research Institutes
    • Diagnostic & Imaging Centers
    • Hospitals
    • Other End Users

    Target Audience

    • Medical Device Manufacturers : Require detailed Asia Pacific market data to develop regional product strategies, identify high-growth country markets, and plan manufacturing and distribution infrastructure investments.
    • Healthcare Facility Operators : Need market forecasts and competitive intelligence to justify capital expenditures for nuclear medicine equipment, plan service expansion, and benchmark performance against regional peers.
    • Pharmaceutical & Radiopharmaceutical Companies : Seek regional market insights to guide radiopharmaceutical development priorities, identify emerging diagnostic applications, and plan commercial launch strategies across Asia Pacific territories.
    • Investment & Private Equity Firms : Require comprehensive market analysis and growth projections to evaluate investment opportunities in Asia Pacific healthcare infrastructure, diagnostic imaging networks, and nuclear medicine service providers.
    • Healthcare Policy & Government Agencies : Need market data and trend analysis to inform healthcare infrastructure planning, diagnostic imaging accessibility initiatives, and regulatory framework development across Asia Pacific regions.

    Key Companies in the Asia Pacific Nuclear Medicine Market

    CompanyHQOwnershipStrongest segments
    BIOMERIEUX S.A.FrancePublic CompanySPECT,PET,Beta Emitters,
    CARL ZEISS AGGermanyPublic CompanyPET (F-18),SPECT (Tc-99m),
    ATS AUTOMATION TOOLING SYSTEMS INCCanadaPublic CompanySPECT,PET,Brachytherapy,
    BRUKER CORPORATIONUnited StatesPublic CompanyPET,SPECT,Beta Emitters,
    SHIMADZU CORPORATIONJapanPublic CompanyPET (F-18),SPECT (Tc-99m),Alpha Emitters,
    VARIAN MEDICAL SYSTEMS, INCUnited StatesPrivate CompanyBrachytherapy,Linear Accelerators,Software Solutions,
    LEONI AGGermanyPrivate CompanyPET Systems,SPECT Systems,Beta Emitters,
    PFIZERUnited StatesPublic CompanyPET (F-18),Beta Emitters (Y-90, Lu-177),SPECT (Tc-99m),
    ELEKTA ABSwedenPublic CompanyBrachytherapy,Linear Accelerators,Stereotactic Radiosurgery,
    NOVARTIS AGSwitzerlandPublic CompanyBeta Emitters,SPECT,Alpha Emitters,
    LANTHEUS HOLDINGS, INC.United StatesPublic CompanyPET,SPECT,Beta Emitters,
    GE HEALTHCAREUnited StatesPublic CompanySPECT,PET,Brachytherapy,
    TELIX PHARMACEUTICALS LIMITEDAustraliaPublic CompanyPET Imaging,Therapeutics,Manufacturing Solutions,
    SIEMENS HEALTHINEERSGermanyPublic CompanyPET,SPECT,Beta Emitters,
    CHINA ISOTOPE & RADIATION CORPORATIONChinaPublic CompanySPECT,PET,Beta Emitters,
    BAYER AGGermanyPublic CompanySPECT,PET,Alpha Emitters,
    CARDINAL HEALTHUnited StatesPublic CompanySPECT,PET,Beta Emitters,

    BIOMERIEUX S.A.

    bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company operates in the diagnostics and life sciences sector.

    CARL ZEISS AG

    Carl Zeiss AG is a German public company founded in 1846 with 5,798 employees. The company specializes in optical systems and precision instruments.

    ATS AUTOMATION TOOLING SYSTEMS INC

    ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 with 7,000 employees. The company provides automation and tooling solutions.

    BRUKER CORPORATION

    Bruker Corporation is a United States public company founded in 1960 with 11,085 employees. The company manufactures scientific instruments and analytical solutions.

    SHIMADZU CORPORATION

    Shimadzu Corporation is a Japanese public company founded in 1875 with 14,649 employees. The company manufactures analytical and scientific instruments.

    VARIAN MEDICAL SYSTEMS, INC

    Varian Medical Systems, Inc. is a United States private company founded in 1948 with 10,000 employees. The company specializes in medical devices and radiation oncology solutions.

    LEONI AG

    Leoni AG is a German private company founded in 1569 with 95,090 employees. The company manufactures cables, wiring systems, and related products.

    PFIZER

    Pfizer is a United States public company founded in 1849 with 75,000 employees. The company is a major pharmaceutical manufacturer and developer.

    ELEKTA AB

    Elekta AB is a Swedish public company founded in 1972 with 4,353 employees. The company specializes in radiation therapy and radiosurgery solutions.

    NOVARTIS AG

    Novartis AG is a Swiss public company founded in 1996 with 75,267 employees. The company is a leading pharmaceutical and healthcare company.

    LANTHEUS HOLDINGS, INC.

    Lantheus Holdings, Inc. is a United States public company founded in 1956 with 1,193 employees. The company develops diagnostic imaging agents and radiopharmaceuticals.

    GE HEALTHCARE

    GE Healthcare is a United States public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.

    TELIX PHARMACEUTICALS LIMITED

    Telix Pharmaceuticals Limited is an Australian public company founded in 2015 with 1,152 employees. The company develops diagnostic and therapeutic radiopharmaceuticals.

    SIEMENS HEALTHINEERS

    Siemens Healthineers is a German public company founded in 1896 with 72,369 employees. The company provides medical imaging, diagnostics, and healthcare solutions.

    CHINA ISOTOPE & RADIATION CORPORATION

    China Isotope & Radiation Corporation is a Chinese public company founded in 1983 with 3,578 employees. The company operates in the isotope and radiation sector.

    BAYER AG

    Bayer AG is a German public company founded in 1863 with 87,757 employees. The company operates in pharmaceuticals, crop science, and consumer health.

    CARDINAL HEALTH

    Cardinal Health is a United States public company founded in 1979 with 55,392 employees. The company is a healthcare services and products distributor.

    Asia Pacific vs. other regions

    HowAsia Pacific compares to the other 3 regional blocs covered in this market.

    Global
    ~USD 21.01 Million · 15.1% wtd CAGR ·
    North America
    ~USD 5801.6 Million · 13.6% wtd CAGR ·
    Europe
    ~USD 3132.3 Million · 14.6% wtd CAGR ·
    Latin America
    ~USD 513.9 Million · 7.5% wtd CAGR ·
    Middle East & Africa
    ~USD 474.4 Million · 11% wtd CAGR ·

    Countries within Asia Pacific - compare and drill down

    Country2025 size (native)
    JapanUSD 1484.4 Million
    ChinaUSD 1339.4 Million
    IndiaUSD 643.4 Million
    South KoreaUSD 352.5 Million
    AustraliaUSD 301.4 Million

    Country market size visualization

    Japan
    USD 1484.4 Million
    China
    USD 1339.4 Million
    India
    USD 643.4 Million
    South Korea
    USD 352.5 Million
    Australia
    USD 301.4 Million

    Reasons to Buy this Report

    • Regional Growth Opportunity : Capture insights into the fastest-growing nuclear medicine market segment with 15.9% CAGR, significantly outpacing global averages and presenting lucrative expansion opportunities for healthcare providers and equipment manufacturers.
    • Country-Level Market Intelligence : Access detailed market sizing and forecasts for key Asia Pacific markets including Japan, China, India, South Korea, and Australia, enabling targeted market entry and investment strategies.
    • Infrastructure Development Trends : Understand healthcare infrastructure investment patterns and facility expansion plans across Asia Pacific nations to identify procurement opportunities and partnership potential with regional healthcare systems.
    • Competitive Landscape Analysis : Gain strategic intelligence on regional competitors, market consolidation trends, and emerging players in the Asia Pacific nuclear medicine sector to inform competitive positioning and M&A strategies.
    • Regulatory and Reimbursement Insights : Navigate complex regional regulatory frameworks and evolving reimbursement policies across Asia Pacific markets to optimize product launches and pricing strategies for nuclear medicine solutions.

    Frequently asked questions

    What is the current size of the Asia Pacific nuclear medicine market?

    The Asia Pacific nuclear medicine market is valued at USD 1,361.1 million in 2025 and is projected to grow to USD 2,850.0 million by 2030.

    What is the growth rate for Asia Pacific nuclear medicine?

    Asia Pacific nuclear medicine is growing at a compound annual growth rate (CAGR) of 15.9% from 2025 to 2030, outpacing the global average.

    What factors are driving growth in Asia Pacific nuclear medicine?

    Key drivers include aging populations, increased healthcare infrastructure investment, rising chronic disease prevalence, regulatory improvements, and growing awareness of early disease detection across Asia Pacific.

    Which technologies are expanding in Asia Pacific nuclear medicine?

    PET (positron emission tomography) and SPECT (single-photon emission computed tomography) imaging technologies are experiencing increased clinical adoption and infrastructure development throughout Asia Pacific.

    How is Asia Pacific positioned in the global nuclear medicine market?

    Asia Pacific represents a high-growth region with a 15.9% CAGR, significantly outpacing global growth, and is expected to capture increasing market share as emerging economies modernize healthcare systems.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

    Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

    Breakdown of Primary Interviews

    Nuclear Medicine Market Size, and Share

    Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Report Metric

    Details

    Siemens Healthineers

    Sr.Sales Manager

    Curium

    General Manager

    Cardinal Health

    Product Sales Specialist

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

    Market Definition

    Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.

    Key Stakeholders

    • Senior Management
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
    • To profile the key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report:

    • Additional country-level analysis of the nuclear medicine market.
    • Profiling of additional market players (up to 3)

    Get the Full Nuclear Medicine Market Report

    Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status